Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Qiagen ( (QGEN) ) has issued an update.
Qiagen disclosed that the Dutch financial markets regulator AFM has notified the company of a substantial shareholding and derivatives position held by Goldman Sachs Group Inc. in Qiagen. According to the notification, Goldman Sachs, through various subsidiaries and instruments including ordinary shares, swaps, options, warrants and convertible bonds, controls an aggregate interest corresponding to 3.15% of Qiagen’s capital and voting rights, largely held indirectly and classified as potential holdings. The filing, made under German securities law transparency rules, signals the presence of a significant institutional investor in Qiagen’s shareholder base, which may affect perceptions of the company’s market profile and trading liquidity, although Qiagen emphasizes it is not responsible for the accuracy of the AFM data.
The most recent analyst rating on (QGEN) stock is a Buy with a $61.00 price target. To see the full list of analyst forecasts on Qiagen stock, see the QGEN Stock Forecast page.
More about Qiagen
Qiagen N.V., based in Venlo, Netherlands, operates in the life sciences and molecular diagnostics industry, and its shares are listed on several European exchanges including Frankfurt as well as on the NYSE and Swiss venues. The company provides sample and assay technologies for molecular testing, serving clinical laboratories, pharmaceutical and biotech companies, and research institutions globally.
Average Trading Volume: 1,827,255
Technical Sentiment Signal: Strong Buy
Current Market Cap: $11.17B
See more data about QGEN stock on TipRanks’ Stock Analysis page.